Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean company engaged in the research and development of platform technology-based immuno-oncology drugs and related IT businesses. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, EU101, and Antibody.
Contact
58 Gasan Digital 1-ro
4th Floor, Room 408, Ace Hansol Tower
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
120
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
A tough year for jackpots however earnings are expected to normalise.
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,475.66 | 22.57 | 0.27% |
| DAX 40 | 26,090.51 | 107.47 | 0.41% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,779.35 | 31.19 | 0.29% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,641.16 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |